Key Takeaways:
Enliven Therapeutics Inc. (Nasdaq: ELVN) announced positive data from a Phase 1 trial of its chronic myeloid leukemia drug, ELVN-001, with 47 percent of patients in a key cohort achieving a major molecular response.
"These results are consistent with our earlier findings demonstrating a favorable safety and tolerability profile, reinforcing ELVN-001's highly selective design," Helen Collins, Chief Medical Officer of Enliven, said. "We believe these data and the overall profile of ELVN-001 support its potential to be the best-in-class ATP-competitive inhibitor for patients living with CML."
The data, from the Phase 1 ENABLE trial, showed robust activity in a heavily pretreated patient population. In patients who had previously received the TKI asciminib, ELVN-001 produced a 52% cumulative major molecular response rate. The drug was well-tolerated across 141 enrolled patients, with less than 10% requiring dose reductions and only 6.4% discontinuing due to adverse events over a median treatment duration of nearly 32 weeks.
The results are significant as they demonstrate ELVN-001's potential in patients who have exhausted other options. The trial enrolled individuals with CML that is relapsed, refractory, or intolerant to available therapies, with 67% having received three or more prior treatments. The company will present updated data at the European Hematology Association 2026 Congress on June 11.
The ENABLE study evaluated ELVN-001, a small molecule kinase inhibitor designed to target the BCR::ABL1 gene fusion that drives CML. The trial included patients with and without the T315I mutation, which confers resistance to most existing tyrosine kinase inhibitors.
The abstract, accepted for an oral presentation at the upcoming EHA congress, detailed results from multiple cohorts. In the mature 80 mg once-daily Phase 1b group, nine of 19 patients, or 47%, reached a major molecular response (MMR), a key measure of deep remission. The findings were particularly strong in patients who had failed prior treatment with Novartis AG's Scemblix (asciminib), where 14 of 27 patients, or 52%, achieved an MMR.
The data suggests ELVN-001's distinct binding mechanism could be effective where other TKIs, including both ATP-competitive and allosteric inhibitors like asciminib, have failed. This complementary action could position ELVN-001 across multiple lines of CML treatment.
The positive data provides a boost for Enliven as it prepares to share more complete results with the investment community. The upcoming presentation will include data from additional patients and longer treatment follow-up, offering a clearer picture of the drug's long-term efficacy and safety.
This article is for informational purposes only and does not constitute investment advice.
